WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007003278) COMPOSITION AND DOSAGE FORM COMPRISING A SOLID OR SEMI-SOLID MATRIX
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/003278    International Application No.:    PCT/EP2006/006026
Publication Date: 11.01.2007 International Filing Date: 22.06.2006
IPC:
A61K 47/22 (2006.01), A61K 9/00 (2006.01)
Applicants: ABBOTT-GMBH & CO. KG [DE/DE]; Max-Planck-Ring 2, 65205 Wiesbaden (DE) (For All Designated States Except US).
ROSENBERG, Jörg [DE/DE]; (DE) (For US Only).
MÄGERLEIN, Markus [DE/DE]; (DE) (For US Only).
BREITENBACH, Jörg [DE/DE]; (DE) (For US Only)
Inventors: ROSENBERG, Jörg; (DE).
MÄGERLEIN, Markus; (DE).
BREITENBACH, Jörg; (DE)
Agent: REITSTÖTTER-KINZEBACH; Reitstötter, Kinzebach & Partner (GbR), Sternwartstrasse 4, 81679 München (DE)
Priority Data:
05014555.6 05.07.2005 EP
60/595,435 05.07.2005 US
Title (EN) COMPOSITION AND DOSAGE FORM COMPRISING A SOLID OR SEMI-SOLID MATRIX
(FR) COMPOSITION ET FORME GALÉNIQUE COMPRENANT UNE MATRICE SOLIDE OU SEMI-SOLIDE
Abstract: front page image
(EN)A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms.
(FR)La présente invention concerne une composition qui comprend une matrice solide ou semi-solide ayant au moins une substance active dispersée uniformément dans celle-ci, la matrice comprenant au moins un agent de formation de matrice pharmaceutiquement acceptable et un composé de type 1,3-bis(lactamyl)butane, en particulier le 1,3-bis(pyrrolidon-1-yl)butane. La substance active est de préférence dispersée dans la matrice à l’état d’une solution solide. L'agent de formation de matrice est de préférence un polymère pharmaceutiquement acceptable. La composition est utile pour la fabrication de formes galéniques pharmaceutiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)